Pulmonx Corporation

LUNG | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.06

+$0.07 (+3.52%)

At close: Sep 22, 2026, 4:00 PM ET

$2.06

$0 (0.00%)

After-hours: Sep 22, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+3.52%

(1D)

Rating

Updated: Sep 18, 2026

38.8

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $87.01M

1D Range

1.99 2.08

52W Range

1.13 2.89

Valuation (TTM)

PE -1.73

PB 2.14

EV/EBITDA -1.96

Valuation (NTM)

Forward PE N/A

Forward PEG 0.23

Price Target $10

Cash Flow

FCF Yield -30.3%

SBC Adj. FCF Yield -40.8%

SBC Impact -34.8%

Margins

Gross Margin 77.1%

Operating Margin -53.0%

FCF Margin -29.1%

Growth (CAGR)

Revenue 3Y | 5Y 13.0% | 15.9%

Dil EPS 3Y | 5Y 12.9% | 5.5%

FCF 3Y | 5Y 17.3% | 14.6%

Returns

ROA -41.9%

ROE -96.7%

ROIC -48.4%

Financial Health

Net Debt

$368K

Current Ratio 4.32

Interest Coverage -12.29

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offerin...

Sector Healthcare

Industry Medical - Devices

Employees 296

IPO Date Sep 30, 2020

Website pulmonx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 11, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$9.75

Upside

+373.30%

Buy (3)

Hold (0)

Sell (0)

Analyst Details ➞